Josep M Sierra

Dr. Josep M Sierra

Laboratory of Molecular Microbiology & Antimicrobials Medical School, Department of Pathology and Experimental Therapeutics, University of Barcelona, Barcelona, Spain
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2017 in Expert Opinion on Biological Therapy
Verified
Journal Article
Closed access
Josep M SierraJosep M Sierra
Josep M Sierra
EFEster Fusté
Ester Fusté
Francesc RabanalFrancesc Rabanal
Francesc Rabanal
TVTeresa Vinuesa
Teresa Vinuesa
MVMiguel Viñas
Miguel Viñas
Introduction: The recent dramatic increase in the incidence of antimicrobial resistance has been recognized by organizations such as the United Nations and World Health Organization as well as the governments of the USA and several European countries. A relatively new weapon in the fight against severe infections caused by multi-drug resistant bacteria is antimicrobial peptides (AMPs). These include colistin, currently regarded as the last line of antimicrobial therapy against multi-drug resistant microorganisms. Areas covered: Here, the authors provide an overview of the current research on AMPs. The focus is AMPs currently being developed for the treatment of recalcitrant bacterial infections, the synergies of AMPs and antibiotics, and the activity of AMPs against biofilm. This review also includes a brief introduction into the use of AMPs in infections caused by Mycobacterium, fungi, and parasites. Expert opinion: In research into new antimicrobials, AMPs are gaining increasing attention. While many are natural and are produced by a wide variety of organisms, others are being newly designed and chemically synthesized in the laboratory to achieve novel antimicrobial agents. The same strategy to fight infections in nature is thus being effectively exploited to safeguard human and animal health.

17 February 2010 in Clinical Orthopaedics and Related Research
Verified
Journal Article
Closed access
PDF file
LFLluís Font-Vizcarra
Lluís Font-Vizcarra
SGSebastián García
Sebastián García
JMJuan C. Martínez-Pastor
Juan C. Martínez-Pastor
Josep M SierraJosep M Sierra
Josep M Sierra
ASAlex Soriano
Alex Soriano
Identifying the etiologic microorganism is essential to guide antimicrobial therapy in prosthetic joint infection.

1 November 2009 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
JMJuan C. MartínEz-Pastor
Juan C. MartínEz-Pastor
EMErnesto MuñoZ-Mahamud
Ernesto MuñoZ-Mahamud
FVFélIx Vilchez
FélIx Vilchez
SGSebastián García-Ramiro
Sebastián García-Ramiro
GBGuillem Bori
Guillem Bori
ASAlex Soriano
Alex Soriano
The aim of our study was to evaluate the outcome of acute prosthetic joint infections (PJIs) due to gram-negative bacilli (GNB) treated without implant removal. Patients with an acute PJI due to GNB diagnosed from 2000 to 2007 were prospectively registered. Demographics, comorbidity, type of implant, microbiology data, surgical treatment, antimicrobial therapy, and outcome were recorded. Classification and regression tree analysis, the Kaplan-Meier survival method, and the Cox regression model were applied. Forty-seven patients were included. The mean age was 70.7 years, and there were 15 hip prostheses and 32 knee prostheses. The median number of days from the time of arthroplasty was 20. The most frequent pathogens were members of the Enterobacteriaceae family in 41 cases and Pseudomonas spp. in 20 cases. Among the Enterobacteriaceae , 14 were resistant to ciprofloxacin, while all Pseudomonas aeruginosa isolates were susceptible to ciprofloxacin. The median durations of intravenous and oral antibiotic treatment were 14 and 64 days, respectively. A total of 35 (74.5%) patients were in remission after a median follow-up of 463 days (interquartile range, 344 to 704) days. By use of the Kaplan-Meier survival curve, a C-reactive protein (CRP) concentration of ≤15 mg/dl ( P = 0.03) and receipt of a fluoroquinolone, when all GNB isolated were susceptible ( P = 0.0009), were associated with a better outcome. By use of a Cox regression model, a CRP concentration of ≤15 mg/dl (odds ratio [OR], 3.57; 95% confidence interval [CI], 1.05 to 12.5; P = 0.043) and receipt of a fluoroquinolone (OR, 9.09; 95% CI, 1.96 to 50; P = 0.005) were independently associated with better outcomes. Open debridement without removal of the implant had a success rate of 74.5%, and the factors associated with good prognosis were a CRP concentration at the time of diagnosis ≤15 mg/dl and treatment with a fluoroquinolone.

1 March 2011 in Clinical Microbiology and Infection
Verified
Journal Article
Closed access
PDF file
FVF. Vilchez
F. Vilchez
JMJ.C. Martínez-Pastor
J.C. Martínez-Pastor
SGS. García-Ramiro
S. García-Ramiro
GBGuillem Bori
Guillem Bori
FMF. Maculé
F. Maculé
ASAlex Soriano
Alex Soriano

1 September 2006 in Clinical Microbiology and Infection
Verified
Journal Article
Open access
PDF file
ASAlex Soriano
Alex Soriano
SGS. García
S. García
GBGuillem Bori
Guillem Bori
MAM. Almela
M. Almela
XGX. Gallart
X. Gallart
JMJ. Mensa
J. Mensa
The best antibiotic regimen for acute prosthetic joint infection, treated without removal of the implant, has not been well-defined. This study describes the use of a protocol based on oral rifampicin combinations to treat 47 cases that were followed prospectively for a 2-year period. The regimen used most commonly was levofloxacin 500 mg/24 h plus rifampicin 600 mg/24 h for a mean duration of 2.7 ± 1 months. The cure rate was 76.9%, and the only independent risk-factor associated with treatment failure was infection caused by methicillin-resistant Staphylococcus aureus or Enterococcus spp. (OR 17.6, p 0.003). Overall, the results suggested that use of oral antibiotics, including rifampicin, for 2–3 months was a good treatment option.

1 October 2005 in Journal of Biological Chemistry
Verified
Journal Article
Open access
PDF file
MSMaria-Rosa Sarrias
Maria-Rosa Sarrias
SRSandra Roselló
Sandra Roselló
FSFernando Sánchez-Barbero
Fernando Sánchez-Barbero
Josep M SierraJosep M Sierra
Josep M Sierra
Jordi VilaJordi Vila
Jordi Vila
LFLozano Francisco
Lozano Francisco
Human Spα is a soluble protein belonging to group B of the scavenger receptor cysteine-rich (SRCR) superfamily for which little functional information is available. It is expressed by macrophages present in lymphoid tissues (spleen, lymph node, thymus, and bone marrow), and it binds to myelomonocytic and lymphoid cells, which suggests that it may play an important role in the regulation of the innate and adaptive immune systems. In the present study we show that recombinant human Spα (rSpα) binds to the surface of several Gram-positive and Gram-negative bacterial strains. Competition studies indicated that such binding is mediated by the recognition of lipoteichoic acid (LTA) and lipopolysaccharide (LPS), respectively, through nonoverlapping sites on the Spα molecule. The most conserved part of LPS (2-keto-3-deoxyoctulosonic acid and lipid A) was shown to be involved in the recognition by Spα. Bacterial binding studies using the SRCR domain 1 of Spα showed that this domain retains both the LPS and LTA binding activities, indicating that both bacterial interacting sites are retained in a single SRCR domain. Furthermore, rSpα induced aggregation of Gram-positive and Gram-negative bacteria strains. On the other hand, rSpα inhibited tumor necrosis factor-α secretion by human monocytes stimulated with LPS or LTA. Binding of Spα to conserved components of bacterial surfaces and modulation of the monocyte response indicate that this molecule is an active constituent of the innate immune response of the host.